The transcription factor NFκB is a well-known player in MM pathogenesis and biology in terms of tumor cell proliferation, expansion and DR [1, 130, 131], and targeting NFκB pathway in MM (e.g. using bortezomib) has recently improved MM therapy [1, 132]. This evidence concerns the gene NFKB1 and Miyoshi myopathy.